4mo
Why BPC 157 will never get FDA Approval: and why it’s not what you think. In late 2023, the FDA put BPC-157—a powerful, endogenous peptide that in preclinical studies accelerates tendon repair and seals "leaky gut"—on a restricted list, effectively banning it from compounding pharmacies. The internet screamed: "Big Pharma is suppressing a miracle cure!" As a surgeon who has spent 20 years as an insider, let me give you the forensic truth: It wasn't malice. It was math. The FDA’s regulatory framework is built to approve single-target chemical inhibitors (like an NSAID). BPC-157 is an "Operating System Update." It heals the gut, the nerves, and the tendons simultaneously. You cannot force a systemic hardware upgrade into a regulatory pathway designed for a single software patch. Add the fact that BPC-157's patent expires in 2033, and the math is clear: no pharmaceutical company was ever going to drop $500M on Phase III trials for a molecule they couldn't monopolize. News broke recently that the FDA is preparing to move 14 restricted peptides—including BPC-157—back to the Category 1 list. Compounding them with a prescription will be available again, which means that more people can get expert opinions and not source them from “research” pharmacies. Because of patent economics, BPC-157 will likely never be a formal "FDA-Approved Drug” however it will continue to be utilized to try to help heal and recover. Much more human research data is needed but when used under the supervision of expert providers can be a useful tool for many conditions (not medical advice). If you have experience with BPC 157 either as a recipient or a provider please share your experience below and let’s discuss 👇 #HumanEngineering #BPC157 #Peptides #FutureOfMedicine #HyperCharge #Biohacking See more comments
More from this author
Explore content categories